Provided by Tiger Trade Technology Pte. Ltd.

SINOMAB BIO-B

1.075
-0.015-1.38%
Volume:1.24M
Turnover:1.32M
Market Cap:1.49B
PE:-10.79
High:1.105
Open:1.105
Low:1.060
Close:1.090
52wk High:2.740
52wk Low:0.990
Shares:1.39B
HK Float Shares:1.39B
Volume Ratio:1.15
T/O Rate:0.09%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.100
ROE:-29.96%
ROA:-9.63%
PB:2.52
PE(LYR):-10.79
PS:223.46

Loading ...

SinoMab BioScience says non-executive directors Chen, Dong resign

Reuters
·
Apr 01

SinoMab BioScience files list of directors with Hong Kong Stock Exchange

Reuters
·
Apr 01

SinoMab Announces Resignation of Two Non-Executive Directors Effective March–April 2026

Bulletin Express
·
Mar 31

SinoMab Announces Updated Board Composition and Committee Assignments

Bulletin Express
·
Mar 31

SINOMAB BIO-B Announces Resignation of Non-Executive Director

Stock News
·
Mar 31

SinoMab Announces Positive Phase 1 Bridging Data for Subcutaneous SM17, Preparing Phase 2 Atopic Dermatitis Trial

Bulletin Express
·
Mar 25

Positive Topline Results from SM17 Route Conversion Phase 1 Bridging Study in China

Stock News
·
Mar 25

SinoMab BioScience announces positive topline results for SM17 China Phase 1 route-switch bridging study; AD Phase 2 in China expected to start by mid-FY2026

Reuters
·
Mar 25

SINOMAB BIO-B (03681) Grants 11.5748 Million Share Options

Stock News
·
Mar 24

SinoMab Grants 11.57 Million Share Options at HK$1.94 to Two Employees, Including One Senior Manager

Bulletin Express
·
Mar 24

SinoMab grants 11,574,840 share options at HKD 1.94 per share

Reuters
·
Mar 24

SinoMab BioScience's 2025 Loss Narrows

MT Newswires Live
·
Mar 24

BRIEF-Sinomab Bioscience Posts Loss For Year Rmb105.0 Million

Reuters
·
Mar 23

SINOMAB BIO-B (03681) Reports Significant Narrowing of Losses in 2025, Major Strides in Pipeline Development and Commercialization

Stock News
·
Mar 23

SinoMab FY2025 loss narrows 43.3% to RMB105 million, total funding available jumps 148.5% to RMB351 million

Reuters
·
Mar 23

SinoMab reports SM17 Phase 1b atopic dermatitis results with 91.7% NRS-4 response rate

Reuters
·
Mar 23

Subsidiary of SINOMAB BIO-B (03681) Terminates Lease Agreement

Stock News
·
Mar 12

SinoMab BioScience - Termination of Lease Agreement Between Unit and Haikou Pharmaceutical Factory

THOMSON REUTERS
·
Mar 12

SinoMab BioScience terminates 20-year lease for Haikou Industry Park property

Reuters
·
Mar 12

SINOMAB BIO-B (03681.HK) Schedules 23 March 2026 Board Meeting to Approve FY2025 Final Results

Bulletin Express
·
Mar 10